ACADIA PHARMACEUTICALS INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.07B | $957.8M | $726.4M | $517.2M | $484.1M | $441.8M | $339.1M |
| Cost of Revenue | — | $89.0M | $81.8M | $41.6M | $10.2M | $19.1M | $10.2M | $11.3M |
| Gross Profit | — | $982.5M | $876.0M | $684.8M | $507.1M | $473.3M | $431.5M | $327.7M |
| Gross Margin | — | 91.7% | 91.5% | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% |
| Operating Expenses | ||||||||
| Research & Development | — | $328.8M | $303.2M | $351.6M | $361.6M | $239.4M | $319.1M | $240.4M |
| SG&A Expense | — | $548.9M | $488.4M | $406.6M | $369.1M | $396.0M | $388.7M | $325.6M |
| Operating Income | — | $104.8M | $230.8M | $-73.4M | $-223.6M | $-170.4M | $-286.6M | $-246.5M |
| Operating Margin | — | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $138.9M | $258.1M | $-51.0M | $-213.4M | $-167.5M | $-281.0M | $-234.4M |
| Income Tax Expense | — | $-252.1M | $31.6M | $10.3M | $2.5M | $351.0K | $611.0K | $876.0K |
| Net Income | — | $391.0M | $226.5M | $-61.3M | $-216.0M | $-167.9M | $-281.6M | $-235.3M |
| Net Margin | — | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% |
| EPS (Basic) | — | $2.32 | $1.37 | $-0.37 | $-1.34 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | — | $2.30 | $1.36 | $-0.37 | $-1.34 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 170.5M | 168.4M | 165.7M | 163.8M | 161.7M | 161.6M | 158.4M | 156.36B |
| Shares Outstanding (Diluted) | 170.5M | 169.9M | 166.4M | 163.8M | 161.7M | 161.6M | 158.4M | 156.36B |
| Dividends Per Share | — | — | — | — | — | — | — | — |